Results of a Six-Month, Randomized, Controlled, Phase-3 Trial Comparing the Efficacy and Safety of Buprenorphine Implants to Placebo Implants, and Sublingual Buprenorphine/Naloxone for Opioid Addiction.
 |
Presented at the American Society of Addiction Medicine (ASAM), Atlanta, Georgia, April, 2012.
Property of Titan Pharmaceuticals, Inc. |
 |
|
Results of a Six-Month, Randomized, Controlled, Phase 3 Trial Comparing the Efficacy and Safety Of Probuphine™ to Placebo Implants, and Suboxone® for Opioid Addiction
 |
Presented by Titan Pharmaceuticals at the 13th annual meeting of International Society of Addiction Medicine (ISAM), Oslo, Norway, September 2011.
Property of Titan Pharmaceuticals, Inc. |
|
|
Safety, Efficacy, and Pharmacokinetics of Probuphine®, a 6-Month Implantable Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Addiction
|
Presented by Titan Pharmaceuticals at American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, December 2009.
Property of Titan Pharmaceuticals, Inc. |
|
|
